{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T13:43:10Z","timestamp":1790689390212,"version":"4.1.0"},"reference-count":40,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"10","license":[{"start":{"date-parts":[[2021,8,28]],"date-time":"2021-08-28T00:00:00Z","timestamp":1630108800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":["Hepatol Commun"],"published-print":{"date-parts":[[2021,10]]},"abstract":"<jats:p>Complications of cirrhosis and portal hypertension (PH) can be reduced by statin therapy. The common loss\u2010of\u2010function variant p.V174A in the solute carrier organic anion transporter gene 1B1 (<jats:italic toggle=\"yes\">SLCO1B1<\/jats:italic>) gene encoding the organic anion transporting polypeptide 1B1 results in decreased hepatic uptake of statins. Our specific aim was to assess the impact of this variant in patients with cirrhosis and statin treatment while controlling for the stage of cirrhosis and other potential confounders with propensity score matching (PSM), availing of a large cohort of genotyped study patients. In total, from 1,088 patients with cirrhosis in two German academic medical centers, PSM yielded 154 patients taking statins and 154 matched controls. The effect on PH was assessed by the liver stiffness\u2013spleen size\u2013to\u2013platelet score (LSPS), and complications of cirrhosis were retrospectively recorded applying consensus criteria. As hypothesized, patients on statin treatment presented less frequently with signs of PH: Esophageal varices (41% vs. 62%; <jats:italic toggle=\"yes\">P<\/jats:italic>\u00a0&lt;\u00a00.001) were less common, and LSPS (4.8\u00a0\u00b1\u00a011.5 vs. 5.6\u00a0\u00b1\u00a06.4; <jats:italic toggle=\"yes\">P<\/jats:italic>\u00a0=\u00a00.01) was reduced. Correspondingly, decompensation events were also reduced in patients on statins (odds ratio [OR]\u00a0=\u00a00.54, 95% confidence interval [CI] 0.32\u20100.90; <jats:italic toggle=\"yes\">P<\/jats:italic>\u00a0=\u00a00.02). When the variant in <jats:italic toggle=\"yes\">SLCO1B1<\/jats:italic> was present in patients on statins, esophageal varices (OR\u00a0=\u00a02.68, 95% CI 1.24\u20105.81; <jats:italic toggle=\"yes\">P<\/jats:italic>\u00a0=\u00a00.01) and bacterial infections (OR\u00a0=\u00a02.50, 95% CI 1.14\u20105.47; <jats:italic toggle=\"yes\">P<\/jats:italic>\u00a0=\u00a00.02) were more common as compared with wild type carriers on statins.<\/jats:p>\n          <jats:p>\n                           <jats:italic toggle=\"yes\">Conclusion:<\/jats:italic> In this cohort, signs and complications of PH were reduced in patients with cirrhosis treated with statins. Notably, this effect was diminished by the common loss\u2010of\u2010function variant in <jats:italic toggle=\"yes\">SLCO1B1<\/jats:italic>. Further prospective studies in independent cohorts are warranted to confirm these genotype\u2010specific observations.<\/jats:p>","DOI":"10.1002\/hep4.1753","type":"journal-article","created":{"date-parts":[[2021,8,28]],"date-time":"2021-08-28T07:56:40Z","timestamp":1630137400000},"page":"1755-1766","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":5,"title":["Protective Effects of Statin Therapy in Cirrhosis Are Limited by a Common SLCO1B1 Transporter Variant"],"prefix":"10.1097","volume":"5","author":[{"given":"Melissa","family":"Merkel","sequence":"first","affiliation":[{"name":"Department of Medicine II,Saarland University Medical Center,Saarland University,Homburg,Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina","family":"Schneider","sequence":"additional","affiliation":[{"name":"Department of Medicine II,Saarland University Medical Center,Saarland University,Homburg,Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robin","family":"Greinert","sequence":"additional","affiliation":[{"name":"Department of Medicine I,Martin Luther University Halle\u2010Wittenberg,Halle,Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Zipprich","sequence":"additional","affiliation":[{"name":"Department of Medicine I,Martin Luther University Halle\u2010Wittenberg,Halle,Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Ripoll","sequence":"additional","affiliation":[{"name":"Department of Medicine I,Martin Luther University Halle\u2010Wittenberg,Halle,Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4450-7201","authenticated-orcid":false,"given":"Frank","family":"Lammert","sequence":"additional","affiliation":[{"name":"Department of Medicine II,Saarland University Medical Center,Saarland University,Homburg,Germany"},{"name":"Hannover Health Sciences Campus,Hannover Medical School (MHH),Hannover,Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8192-0575","authenticated-orcid":false,"given":"Matthias C.","family":"Reichert","sequence":"additional","affiliation":[{"name":"Department of Medicine II,Saarland University Medical Center,Saarland University,Homburg,Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2021,8,28]]},"reference":[{"key":"hep41753-bib-0001-20241015","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.jhep.2005.10.013","article-title":"Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies","volume":"44","year":"2006","journal-title":"J Hepatol"},{"key":"hep41753-bib-0002-20241015","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.jhep.2018.07.019","article-title":"Statins: old drugs as new therapy for liver diseases?","volume":"70","year":"2019","journal-title":"J Hepatol"},{"key":"hep41753-bib-0003-20241015","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1053\/j.gastro.2009.01.043","article-title":"Simvastatin lowers portal pressure in patients with cirrhosis and portal hypertension: a randomized controlled trial","volume":"136","year":"2009","journal-title":"Gastroenterology"},{"key":"hep41753-bib-0004-20241015","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1002\/hep.21673","article-title":"Atorvastatin lowers portal pressure in cirrhotic rats by inhibition of RhoA\/Rho\u2010kinase and activation of endothelial nitric oxide synthase","volume":"46","year":"2007","journal-title":"Hepatology"},{"key":"hep41753-bib-0005-20241015","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1016\/j.dld.2015.07.156","article-title":"Three months of simvastatin therapy vs. placebo for severe portal hypertension in cirrhosis: a randomized controlled trial","volume":"47","year":"2015","journal-title":"Dig Liver Dis"},{"key":"hep41753-bib-0006-20241015","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1097\/MEG.0000000000001006","article-title":"Effects of atorvastatin on portal hemodynamics and clinical outcomes in patients with cirrhosis with portal hypertension: a proof\u2010of\u2010concept study","volume":"30","year":"2018","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"hep41753-bib-0007-20241015","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1053\/j.gastro.2016.01.004","article-title":"Addition of simvastatin to standard therapy for the prevention of variceal rebleeding does not reduce rebleeding but increases survival in patients with cirrhosis","volume":"150","year":"2016","journal-title":"Gastroenterology"},{"key":"hep41753-bib-0008-20241015","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1111\/apt.12430","article-title":"Statin use and infections in Veterans with cirrhosis","volume":"38","year":"2013","journal-title":"Aliment Pharmacol Ther"},{"key":"hep41753-bib-0009-20241015","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1053\/j.gastro.2015.10.007","article-title":"Statins are associated with a decreased risk of decompensation and death in Veterans with hepatitis C\u2010related compensated cirrhosis","volume":"150","year":"2016","journal-title":"Gastroenterology"},{"key":"hep41753-bib-0010-20241015","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.ijcard.2011.07.048","article-title":"Managing the underestimated risk of statin\u2010associated myopathy","volume":"159","year":"2012","journal-title":"Int J Cardiol"},{"key":"hep41753-bib-0011-20241015","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1056\/NEJMoa0801936","article-title":"SLCO1B1 variants and statin\u2010induced myopathy\u2014a genomewide study","volume":"359","year":"2008","journal-title":"N Engl J Med"},{"key":"hep41753-bib-0012-20241015","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1038\/s41397-018-0054-0","article-title":"Association between SLCO1B1 T521C polymorphism and risk of statin\u2010induced myopathy: a meta\u2010analysis","volume":"18","year":"2018","journal-title":"Pharmacogenomics J"},{"key":"hep41753-bib-0013-20241015","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1124\/dmd.108.024315","article-title":"Methotrexate pharmacokinetics in transgenic mice with liver\u2010specific expression of human organic anion\u2010transporting polypeptide 1B1 (SLCO1B1)","volume":"37","year":"2009","journal-title":"Drug Metab Dispos"},{"key":"hep41753-bib-0014-20241015","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1124\/pr.110.002857","article-title":"Organic anion transporting polypeptide 1B1: a genetically polymorphic transporter of major importance for hepatic drug uptake","volume":"63","year":"2011","journal-title":"Pharmacol Rev"},{"key":"hep41753-bib-0015-20241015","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1097\/01.fpc.0000230416.82349.90","article-title":"SLCO1B1 polymorphism markedly affects the pharmacokinetics of simvastatin acid","volume":"16","year":"2006","journal-title":"Pharmacogenet Genomics"},{"key":"hep41753-bib-0016-20241015","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1038\/sj.clpt.6100220","article-title":"Different effects of SLCO1B1 polymorphism on the pharmacokinetics of atorvastatin and rosuvastatin","volume":"82","year":"2007","journal-title":"Clin Pharmacol Ther"},{"key":"hep41753-bib-0017-20241015","doi-asserted-by":"crossref","first-page":"639","DOI":"10.3109\/00498254.2011.562566","article-title":"Impact of SLCO1B1 (OATP1B1) and ABCG2 (BCRP) genetic polymorphisms and inhibition on LDL\u2010C lowering and myopathy of statins","volume":"41","year":"2011","journal-title":"Xenobiotica"},{"key":"hep41753-bib-0018-20241015","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1186\/s13063-015-0594-4","article-title":"The INCA trial (Impact of NOD2 genotype\u2010guided antibiotic prevention on survival in patients with liver Cirrhosis and Ascites): study protocol for a randomized controlled trial","volume":"16","year":"2015","journal-title":"Trials"},{"key":"hep41753-bib-0019-20241015","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1053\/j.gastro.2015.09.040","article-title":"Transient and 2\u2010dimensional shear\u2010wave elastography provide comparable assessment of alcoholic liver fibrosis and cirrhosis","volume":"150","year":"2016","journal-title":"Gastroenterology"},{"key":"hep41753-bib-0020-20241015","first-page":"S1","article-title":"2013 ACC\/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines","volume":"129","year":"2014","journal-title":"Circulation"},{"key":"hep41753-bib-0021-20241015","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/j.jhep.2018.03.024","article-title":"EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis","volume":"69","year":"2018","journal-title":"J Hepatol"},{"key":"hep41753-bib-0022-20241015","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1002\/hep.27210","article-title":"Hepatic encephalopathy in chronic liver disease: 2014 Practice Guideline by the American Association for the Study of Liver Diseases and the European Association for the Study of the Liver","volume":"60","year":"2014","journal-title":"Hepatology"},{"key":"hep41753-bib-0023-20241015","doi-asserted-by":"crossref","first-page":"2328","DOI":"10.1002\/hep.25947","article-title":"Second infections independently increase mortality in hospitalized patients with cirrhosis: the North American consortium for the study of end\u2010stage liver disease (NACSELD) experience","volume":"56","year":"2012","journal-title":"Hepatology"},{"key":"hep41753-bib-0024-20241015","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1053\/j.gastro.2012.10.001","article-title":"Elastography, spleen size, and platelet count identify portal hypertension in patients with compensated cirrhosis","volume":"144","year":"2013","journal-title":"Gastroenterology"},{"key":"hep41753-bib-0025-20241015","doi-asserted-by":"crossref","first-page":"1","DOI":"10.15436\/2471-0601.16.1249","article-title":"Evaluation of liver and spleen transient elastography in the diagnosis of esophageal varices","volume":"2","year":"2016","journal-title":"J Gastrointestinal Disorders Liver Function"},{"key":"hep41753-bib-0026-20241015","doi-asserted-by":"crossref","first-page":"2173","DOI":"10.1002\/hep.28824","article-title":"Noninvasive tools and risk of clinically significant portal hypertension and varices in compensated cirrhosis: the \"Anticipate\" study","volume":"64","year":"2016","journal-title":"Hepatology"},{"key":"hep41753-bib-0027-20241015","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1002\/hep.29302","article-title":"Comparison of laboratory tests, ultrasound, or magnetic resonance elastography to detect fibrosis in patients with nonalcoholic fatty liver disease: a meta\u2010analysis","volume":"66","year":"2017","journal-title":"Hepatology"},{"key":"hep41753-bib-0028-20241015","article-title":"Diagnostic accuracy of APRI, AAR, FIB\u20104, FI, King, Lok, Forns, and FibroIndex scores in predicting the presence of esophageal varices in liver cirrhosis: a systematic review and meta\u2010analysis","volume":"94","year":"2015","journal-title":"Medicine (Baltimore)"},{"key":"hep41753-bib-0029-20241015","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1038\/s41586-020-2308-7","article-title":"The mutational constraint spectrum quantified from variation in 141,456 humans","volume":"581","year":"2020","journal-title":"Nature"},{"key":"hep41753-bib-0030-20241015","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1093\/aje\/kwj149","article-title":"Variable selection for propensity score models","volume":"163","year":"2006","journal-title":"Am J Epidemiol"},{"issue":"Suppl 1","key":"hep41753-bib-0031-20241015","first-page":"S54","article-title":"Current management of portal hypertension","volume":"38","year":"2003","journal-title":"J Hepatol"},{"key":"hep41753-bib-0032-20241015","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1053\/j.gastro.2003.12.007","article-title":"Simvastatin enhances hepatic nitric oxide production and decreases the hepatic vascular tone in patients with cirrhosis","volume":"126","year":"2004","journal-title":"Gastroenterology"},{"key":"hep41753-bib-0033-20241015","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1053\/j.gastro.2019.01.026","article-title":"Effects of hypercholesterolemia and statin exposure on survival in a large national cohort of patients with cirrhosis","volume":"156","year":"2019","journal-title":"Gastroenterology"},{"key":"hep41753-bib-0034-20241015","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1016\/j.cgh.2017.04.039","article-title":"Statin use and risk of cirrhosis and related complications in patients with chronic liver diseases: a systematic review and meta\u2010analysis","volume":"15","year":"2017","journal-title":"Clin Gastroenterol Hepatol"},{"key":"hep41753-bib-0035-20241015","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1592\/phco.27.3.325","article-title":"Statins and the risk of pneumonia: a population\u2010based, nested case\u2010control study","volume":"27","year":"2007","journal-title":"Pharmacotherapy"},{"key":"hep41753-bib-0036-20241015","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/S0140-6736(06)68041-0","article-title":"Statins and sepsis in patients with cardiovascular disease: a population\u2010based cohort analysis","volume":"367","year":"2006","journal-title":"The lancet"},{"key":"hep41753-bib-0037-20241015","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1097\/01.CCM.0000207345.92928.E4","article-title":"Statin use and mortality within 180 days after bacteremia: a population\u2010based cohort study","volume":"34","year":"2006","journal-title":"Crit Care Med"},{"key":"hep41753-bib-0038-20241015","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1136\/gutjnl-2019-318237","article-title":"Cirrhosis as new indication for statins","volume":"69","year":"2020","journal-title":"Gut"},{"key":"hep41753-bib-0039-20241015","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1002\/cld.866","article-title":"Use of statins in patients with and without liver disease","volume":"15","year":"2020","journal-title":"Clin Liver Dis (Hoboken)"},{"key":"hep41753-bib-0040-20241015","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S2468-1253(19)30320-6","article-title":"Safety of two different doses of simvastatin plus rifaximin in decompensated cirrhosis (LIVERHOPE\u2010SAFETY): a randomised, double\u2010blind, placebo\u2010controlled, phase 2 trial","volume":"5","year":"2020","journal-title":"Lancet Gastroenterol Hepatol"}],"container-title":["Hepatology Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/hep4.1753","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/hep4.1753","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.lww.com\/10.1002\/hep4.1753","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,15]],"date-time":"2024-10-15T22:20:05Z","timestamp":1729030805000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1002\/hep4.1753"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,28]]},"references-count":40,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.1002\/hep4.1753","relation":{},"ISSN":["2471-254X","2471-254X"],"issn-type":[{"value":"2471-254X","type":"print"},{"value":"2471-254X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,28]]},"assertion":[{"value":"2021-01-05","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-05-06","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}